Compare WVE & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | ASTH |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | WVE | ASTH |
|---|---|---|
| Price | $16.01 | $23.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $27.53 | ★ $41.33 |
| AVG Volume (30 Days) | ★ 12.9M | 489.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | $109,230,000.00 | ★ $2,896,452,000.00 |
| Revenue This Year | N/A | $58.37 |
| Revenue Next Year | $31.09 | $25.48 |
| P/E Ratio | ★ N/A | $122.28 |
| Revenue Growth | ★ 103.75 | 68.17 |
| 52 Week Low | $5.28 | $20.12 |
| 52 Week High | $21.73 | $39.97 |
| Indicator | WVE | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 49.51 |
| Support Level | $6.93 | $20.64 |
| Resistance Level | $21.73 | $23.23 |
| Average True Range (ATR) | 1.51 | 0.95 |
| MACD | 1.14 | 0.35 |
| Stochastic Oscillator | 61.45 | 94.93 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.